Growth Metrics

Corcept Therapeutics (CORT) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 0.77.

  • Corcept Therapeutics' Equity Ratio fell 581.12% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year decrease of 581.12%. This contributed to the annual value of 0.81 for FY2024, which is 83.03% down from last year.
  • Corcept Therapeutics' Equity Ratio amounted to 0.77 in Q3 2025, which was down 581.12% from 0.79 recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Equity Ratio ranged from a high of 0.92 in Q1 2021 and a low of 0.77 during Q3 2025
  • Moreover, its 5-year median value for Equity Ratio was 0.84 (2024), whereas its average is 0.85.
  • In the last 5 years, Corcept Therapeutics' Equity Ratio crashed by 1244.57% in 2023 and then soared by 480.76% in 2024.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Equity Ratio stood at 0.89 in 2021, then fell by 3.01% to 0.86 in 2022, then decreased by 5.22% to 0.82 in 2023, then dropped by 0.83% to 0.81 in 2024, then decreased by 5.1% to 0.77 in 2025.
  • Its last three reported values are 0.77 in Q3 2025, 0.79 for Q2 2025, and 0.81 during Q1 2025.